<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The management of T2DM requires aggressive treatment to achieve glycemic and <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factor</z:e> goals </plain></SENT>
<SENT sid="1" pm="."><plain>In this setting, <z:chebi fb="0" ids="6801">metformin</z:chebi>, an old and widely accepted first line agent, stands out not only for its antihyperglycemic properties but also for its effects beyond glycemic control such as improvements in <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, hemostasis and <z:mp ids='MP_0003674'>oxidative stress</z:mp>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles, and <z:e sem="disease" ids="C0856151" disease_type="Disease or Syndrome" abbrv="">fat redistribution</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>These properties may have contributed to the decrease of adverse cardiovascular outcomes otherwise not attributable to <z:chebi fb="0" ids="6801">metformin</z:chebi>'s mere antihyperglycemic effects </plain></SENT>
<SENT sid="3" pm="."><plain>Several other classes of oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents have been recently launched, introducing the need to evaluate the role of <z:chebi fb="0" ids="6801">metformin</z:chebi> as initial therapy and in combination with these newer drugs </plain></SENT>
<SENT sid="4" pm="."><plain>There is increasing evidence from in vivo and in vitro studies supporting its anti-proliferative role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and possibly a neuroprotective effect </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi>'s negligible risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in monotherapy and few drug interactions of clinical relevance give this drug a high safety profile </plain></SENT>
<SENT sid="6" pm="."><plain>The tolerability of <z:chebi fb="0" ids="6801">metformin</z:chebi> may be improved by using an appropiate dose titration, starting with low doses, so that side-effects can be minimized or by switching to an extended release form </plain></SENT>
<SENT sid="7" pm="."><plain>We reviewed the role of <z:chebi fb="0" ids="6801">metformin</z:chebi> in the treatment of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and describe the additional benefits beyond its glycemic effect </plain></SENT>
<SENT sid="8" pm="."><plain>We also discuss its potential role for a variety of insulin resistant and <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">pre-diabetic</z:e> states, <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> associated with <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV disease</z:e>, <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and neuroprotection </plain></SENT>
</text></document>